CSPC Pharmaceutical Group Limited (CSPC PHARMA) filed its Monthly Return for Equity Issuer to the Hong Kong Stock Exchange for the period ended 30 September 2026, confirming a stable capital structure over the month.

Issued Share Capital • Ordinary shares in issue remained unchanged at 11.52 billion, with zero treasury shares recorded at both the beginning and end of September. • No new shares were issued, repurchased, cancelled, or otherwise moved during the reporting period.

Public Float Compliance • CSPC PHARMA reconfirmed compliance with the Main Board’s minimum 25% public-float requirement as at 30 September 2026.

Share Option Portfolio • Two active share-option schemes account for 1.15 billion outstanding options: – 2015 Scheme (adopted 9 Dec 2015): 1.30 million options outstanding. – 2026 Scheme (adopted 28 May 2026): 1.15 billion options outstanding. • No options were exercised, cancelled, or lapsed in September. • The outstanding options represent approximately 10.01% of the current issued ordinary share base and, if fully exercised, could expand the share count to roughly 12.68 billion.

Other Equity Instruments • The company reported no outstanding or new warrants, convertibles, or other equity-linked instruments, and no Hong Kong Depositary Receipt activity.

Governance Note • The filing was signed off by Company Secretary Mr. Lo Tai On on 2 October 2026, confirming the accuracy of disclosures and adherence to Exchange requirements.